Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0MS2T
|
|||
| Drug Name |
BCMA-specific CAR-expressing T Lymphocytes
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Plasma cell myeloma [ICD-11: 2A83.1; ICD-10: C90.0] | Phase 1 | [1] | |
| Company |
Fred Hutchinson Cancer Research Center
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell maturation protein (TNFRSF17) | Target Info | CAR-T-Cell-Therapy | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03502577) BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (LY3039478) to Treat Relapsed or Persistent Multiple Myeloma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.